Treats generalized myasthenia gravis (gMG). Sold as Vyvgart. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Efgartigimod Alfa (sold as Vyvgart), first approved Dec 17, 2021, with 3 new uses approved and 0 published complete response letters.
| Efgartigimod in Anti-NMDA Receptor Encephalitis.Encephalitis Autoimmune · Beijing Tongren Hospital | Phase 2 | Recruiting | Sep 16, 2026 |
| Efficacy and Safety of Efgartigimod in the Treatment of Guillain-Barré Syndrome(GREAT)Guillain-Barré Syndrome · Beijing Tiantan Hospital | Phase 2 | Not yet recruiting | Sep 8, 2026 |
| A Study to Learn About How Well the Medicine Efgartigimod Works to Treat Autoimmune Encephalitis In Children 12 Years or Older and AdultsAutoimmune Encephalitis (AE) · argenx | Phase 2 | Not yet recruiting | May 13, 2026 |
| Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia GravisMyasthenia Gravis · Janssen Research & Development, LLC | Phase 3 | Recruiting | Oct 16, 2025 |
| Evaluate the Benefit of Corticoid Sparing in Elderly With Generalized AntiRAch Myasthenia Gravis Treated With IV or SC EfgartigimodMyasthenia Gravis, Generalized · Centre Hospitalier Universitaire de Nice | Phase 4 | Recruiting | Jul 18, 2025 |
| A Study of Efgartigimod in Patients With IgG4-Related DiseaseIgG4-related Disease · Stanford University | Phase 2 | Active, not recruiting | Jun 17, 2025 |
| Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART)Epidermolysis Bullosa (EB), Epidermolysis Bullosa Acquisita · M. Peter Marinkovich | Phase 1 / Phase 2 | Not yet recruiting | Jun 9, 2025 |
| Efgartigimod for the Treatment of Guillain-Barré SyndromeGuillain-Barre Syndrome (GBS) · Zhongming Qiu | Phase 2 / Phase 3 | Not yet recruiting | Mar 20, 2025 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA